NCT05504837

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Krystal Biotech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Conditions

• Cystic Fibrosis

Interventions

Type	Name	Description
BIOLOGICAL	KB407 (Nebulization)	Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR

Timeline

• Start date: 2023-06-30
• Primary completion: 2025-12-01
• Completion: 2026-01-01
• First posted: 2022-08-17
• Last updated: 2025-08-21

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study